搜尋結果

共 1860 個結果
頁數:1...13 14 15 16 17 18 19 20 21 ...93

當科學遇上政治:從一項口罩研究說起

去年10月,由美國疾病控制和預防中心(CDC)審批和出版的期刊Morbidity and Mortality ...全文

今日信報理財投資經濟3.0曾國平2022年02月17日

Europe must be Africa’s partner of choice

After being postponed several times because of the COVID-19 pandemic, this month’s European Union-African Union Summit in Brussels (February 17-18) will bring together European and African heads of st ...More

EJ Insight2022-02-16

倫敦租房有感

最近天天上網站Rightmove和Zoopla,要找在倫敦各區出租的房子,希望下星期返回英國時,可以即時入伙, ...全文

今日信報副刊文化酒食浪遊劉群章2022年02月16日

How investors can update their income strategies

It has been more than a decade since the 2008 financial crisis, yet the main challenge for investors hasn’t changed: finding reliable income to compensate for feeble bond yields without taking undue r ...More

EJ Insight2022-02-15

Climate accountability now

It has been 30 years since world leaders gathered in Rio de Janeiro and agreed on a set of measures to start the global mobilization against human-caused climate change and to meet the imperative of a ...More

EJ Insight2022-02-15

Fraud abroad: How SMBs can expand globally and stay secure

One in four consumers will continue to shop from foreign online stores, even after the pandemic, according to a recent Ipsos survey of 13,000 respondents across the world’s biggest eCommerce markets. ...More

EJ Insight2022-02-14

Crisis management requires good use of innovative technology

The Omicron outbreak is very severe. In early January, many people listed as close contacts were sent to Penny's Bay for quarantine. The blunders and hiccups of the quarantine camp have left many resi ...More

EJ Insight2022-02-14

從足球員確診看疫症影響

從曼聯的普巴(Paul Pogba)到AC米蘭的伊巴謙莫域(Zlatan Ibrahimovi),再到當時仍在 ...全文

今日信報理財投資經濟3.0梁天卓2022年02月12日

中藥防治「新冠」是草還是寶之三

2022年1月22日,北京中醫藥大學中醫疫病研究院、教育部中醫養生學重點實驗室、中醫養生學北京市重點實驗室向北 ...全文

今日信報副刊文化自講自治黃譚智媛2022年02月11日

推高疫苗接種率的成本效益

為了推高疫苗接種率,政府可以去到幾盡?政府早前宣布: 「疫苗通行證」本月24日起推行,所有進入表列處所的人士須 ...全文

今日信報理財投資經濟3.0梁天卓2022年02月11日

Make capitalism competitive again

Not every sitting US president invites comparisons with a Roosevelt, let alone two members of that storied family. Since taking office just over a year ago, Joe Biden has frequently been likened to Pr ...More

EJ Insight2022-02-10

China’s big picture

China has puzzled me for quite some time now, not least because some of its biggest current challenges appear to be self-induced. I have been fascinated with the Chinese economy since I first visited ...More

EJ Insight2022-02-10

清零或毒存?只看一關鍵…

新年過後,香港疫情趨於失控,每日新增確診人數翻倍增加。愈來愈多人因此憂慮,不論「清零」抑或「動態清零」均已不切 ...全文

今日信報時事評論李道2022年02月10日

The dilemma Hong Kong confronts

We're in a COVID limbo. Before us is a fork – a fork th ...全文

今日信報時事評論EJ InsightBrian Wong2022年02月09日

【輪證贏家】恒指熊追小時圖繼續向下

噚日收咗市之後一支箭咁撲出門口,事關約咗師兄老劉劉兆昌去佢地頭搵佢食Tea(兩條友隻半隻雞再加堆薯條,咁算唔算 ...全文

即時新聞即巿股評2022年02月08日

A balanced response to inflation

Although some supply shortages were anticipated as the global economy reopened after the COVID-19 lockdowns, they have proved more pervasive, and less transitory, than had been hoped. In a market econ ...More

EJ Insight2022-02-08

The dilemma Hong Kong confronts

We’re in a COVID limbo. Before us is a fork – a fork that takes us down two paths. The first constitutes reopening Hong Kong to our very own country – to dissolve the quarantine and isolation requirem ...More

EJ Insight2022-02-07

高盛:藥明發盈喜 連升3日重上80元 留意貼價購18980、高槓桿購19984,貼牛50177

正股表現:藥明生物(02269) 近日觸底反彈,今早繼續造好。早上開市隨即重上80元水平,最高見82.45元, ...全文

港股360輪證攻略2022年02月07日

【異動股】藥明生物升3% 料全年純利增近倍

藥明生物(02269)發盈喜,料全年純利增近倍,股價今早高開3.1%報82元,最新升2%報81.15元,成交逾 ...全文

即時新聞港股直擊2022年02月07日

Submerged by COVID

The wildfire spread of the Omicron variant adds a new element of uncertainty to the global economy. But when it comes to emerging markets, the consensus view is that these countries’ prospects remain ...More

EJ Insight2022-02-04

頁數:1...13 14 15 16 17 18 19 20 21 ...93

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。